预约演示
BioNTech adds STING to oncology portfolio in €40M small molecule licensing deal with Ryvu
2022-11-30
免疫疗法引进/卖出疫苗临床2期
A number of drug developers have been stung in their attempts to chase the STING pathway.
It may have become a household name during the pandemic, but the drumbeat oSTINGouncements from BioNTech this year are a reminder that the German company has far more varied ambitions. With infectious disease and cancer vaccines in various stages of development, the biotech has now licensed a variety of small-molecule programs from Poland’s Ryvu Therapeutics.
Under the multi-target agreement, BioNtech will pay Ryvu 20 million euros ($20.7 million) upfront along with an equity investment of the same amount. Split into two parts, one side of the deal will see BioNTech secancern exclusive global license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules, includRyvu Therapeuticsies and in combination with other therapies.
The stimulator of interferon genesBioNtech pathway is an immunity pathway that plays a key role both in responding to infections and autoimmune diseases as well as providing antitumor immunity. PrecliniBioNTechies have shown that Ryvu’s STING agonists were able to activate proinflaSTINGry cytokine production and long-lasting immune responses, BioNTech said in a release.
The stimulator of interferon genes (STING)the two companies jointly undertake drug discovery and research projects to infectionsltiplautoimmune diseasesograms for targets selected by BioNTech. The primary focus of these targets will be iSTING modulation for oncology, but the biotech has the option to push into other disease areas. Once candidaBioNTech been singled out for development, BioNTech will have the option to license them.
BioNTecholecules targeting novel immune signaling pathways have a great potential to increase the efficacy of cancer immunotherapies,” said BioNTech CEO Ugur Sahin, M.D., in a Nov. 30 release. “The collaboration with Ryvu provides us with the opportunity to complement our immunotherapy pipeline with a portfolio of potent immunomodulatory molecules.”
BioNTech’s oncology pipeline is already well underway. The company has 19 candidates across a total of 24 clincancerrials, including CAR-T cBioNTechapy candidate BNT211. The furthest developed are phase 2 trials of melanoma vaccine BNT111 and BNT113 for HPV16-positive cancers—which both use the biotech’s FixVac platform—plus a pancreatic cancer hopeful called autogene cevumeran and the bispecific antibody immune checkpoint modulator BNT311.
BioNTech of drug developers have been stung in their attempts to chase the STING pathway. In 2019, Novartis ended work on an intratumoral STING pathway activator BNT211ate developed by Aduro Biotech, while Nimbus Thmelanomacs also pBNT111 awayBNT113the pHPV16-positive cancersear.pancreatic cancercevumeranBNT311
BioNTech isn’t the only one who still sees potential, however. AstraZeneca STINGed the global rightNovartisearch, develop and bring to marSTING pathway activatorpounds for $12 million uAduro Biotech-star ThNimbus Therapeuticsr.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。